(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of 14.97% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Foghorn Therapeutics's revenue in 2024 is $34,155,000.On average, 3 Wall Street analysts forecast FHTX's revenue for 2024 to be $1,604,862,279, with the lowest FHTX revenue forecast at $1,111,395,753, and the highest FHTX revenue forecast at $1,915,465,680. On average, 2 Wall Street analysts forecast FHTX's revenue for 2025 to be $1,843,742,132, with the lowest FHTX revenue forecast at $1,133,530,024, and the highest FHTX revenue forecast at $2,553,954,240.
In 2026, FHTX is forecast to generate $2,236,412,596 in revenue, with the lowest revenue forecast at $1,748,607,336 and the highest revenue forecast at $2,724,217,856.